The Canadian Invasive Antifungal Drugs market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period (2019- 2028).
Among the population of Canada (35.5 million in 2014), it was estimated that approximately 1.8% are affected by a severe fungal infection. Recurrent vulvovaginal candidiasis, severe asthma with fungal sensitization, and allergic bronchopulmonary aspergillosis are the most frequent infections, with population prevalences of 498,688, 73,344, and 61,854 cases, respectively. Over 3000 invasive fungal infections are estimated to occur annually, with incidences of 2068 cases of invasive candidiasis, 566 cases of invasive aspergillosis, 252 cases of Pneumocystis pneumonia, 99 cases of endemic mycoses, and 63 cases of cryptococcosis. A growing and aging population, increasing incidence of fungal conditions, the development and approval of new products, additional indications and formulations, and increased Canadian market penetration will be driving factors for the market over the next decade.
The major factors augmenting the growth of the Invasive antifungal drugs market include increasing awareness about the myriad fungal infections, increasing the number of antifungal drugs available over the counter (OTC). Rising consumption of antifungal medications in developing regions for various medical conditions and the invasive procedures at hospitals also give rise to the risk of fungal infections at an alarming rate. This increase in prevalence and incidence rate of fungal infection cases propels the need for drugs that enable efficient and fast treatment of the disease.